Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy-Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review.

Open Forum Infect Dis · 2022 · PMC8900931 · PMID 35265729

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceP = .060so close (0.05 < p ≤ 0.1)

showed a trendno p-value reported

Median CD4 + /CD8 + ratio showed a trend toward improvement from baseline (0.83 [IQR, 0.70–1.00]) to 48 weeks postswitch to dolutegravir plus lamivudine (0.86 [IQR, 0.68–1.06]) but did not reach statistical significance ( P = .060).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.